Drug Approval | January 21, 2022
Bristol Myers Squibb receives approval for Abecma in Japan
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
First of its kind integrated Heart Health Programme on its Health Station ‘hPod’
Unlike most data analysis services, Dolomite Bio will accept sample sizes ranging from as little as one sample, to as many as the research project requires
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
First launches expected in H1 2022
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
This is the company’s first partnership arrangement in China
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
Subscribe To Our Newsletter & Stay Updated
